Clinical Trial Update: ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial ACCENT is evaluating AMP945 in combination with nab-paclitaxel and gemcitabine for pancreatic cancer in Phase 1/2; the study is currently active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• AMP945
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Amplia Therapeutics Limited | Conditions: Pancreatic Cancer, PDAC | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING